Pegasus Biotech Inc. is a full-service biotechnology contract research organization that offers process and analytical development services to the global pharma industry. With expertise in vaccine and biopharmaceutical development, they are leaders in DNA vaccine development.
Recently, Pegasus Biotech Inc. has announced the launch of a new technology that allows scientists to control the production of DNA, thanks to Dr. Patrick Slaine’s redesign of plasmid DNA replication. This BPE plasmid technology uses a patented origin that remains inactive during fermentation but can be activated at high cell densities to increase replication levels significantly. Unlike existing technology, it does not rely on antibiotic resistance selection markers and contains minimal bacterial sequences.
This technology meets project requirements of low cost, minimal bacterial sequences, high expression, and no antibiotic resistance selection marker, paving the way for the development of new vaccines and gene-therapy products. Daniel Wilson, COO of Pegasus Biotech Inc., emphasized the transformative potential of this technology in applications where cost of goods sold (COGS) and patient safety are critical factors.
Pegasus Biotech aims to help clients bring cutting-edge innovation to the human and animal health markets globally by offering services spanning seed-to-formulation process development and associated analytical development. For more information about Pegasus’ services, visit their website at www.pegasusbio.com or contact Daniel Wilson at 1-855-498-3398 via email at [email protected].
